Johannesburg — The U.S. Food and Drug Administration (FDA) has authorized the marketing of IQOS, Philip Morris International‘s (PMI) electrically heated tobacco system, as a modified risk tobacco product (MRTP). IQOS is reportedly the first and only electronic nicotine product to be granted marketing orders through the FDA’s MRTP process. The IQOS System heats tobacco but does not burn it and therefore significantly reduces the production of harmful and potentially harmful chemicals.
PMI‘s Chief Executive Officer, André Calantzopoulos, Vice President, Strategic and Scientific Communications, Dr. Moira Gilchrist and Tommaso Di Giovanni the Vice President Global Communications, answered questions from journalists, scientists and doctors interested in the FDA’s decision to authorize the product.
While clarifying what reduced exposure means and how it stands to reduce risk and harm according to this decision of the FDA, PMI says they’ve done 4 different clinical studies in adult smokers where they asked them either to stay with their regular cigarettes, to quit completely for the duration of the study or to switch to IQOS and they did these studies either short term (5 days) or longer term (3 months). Those studies show that the group that switched to IQOS came very close to the levels of exposure to potentially harmful chemicals that they measured to those who quit completely for the duration of the study, so there is a very significant difference between those who continue to smoke and those who switch to IQOS.
“This might have been the evidence that led essentially to the information that FDA authorized on July 7. When it comes to reduced risk and reduced harm people have to remember that smoking-related diseases take a long time to actually manifest themselves and be able to be measured in somebody. For example something like lung cancer takes decades to actually develop and be measurable in somebody who’s suffering from it, it’s not something that can be measured in short term studies,” said Dr Gilchrist.
“What PMI has done is to look into things called risk-markers – these are markers that can be measure again in blood and urine, they indicate whether somebody has an increased or decreased risk of getting one of those smoking related diseases but to measure the actual smoking-related diseases you need something called epidemiological evidence and that means the long-term follow-up of people who switched over many years. What’s great about the FDA authorization is they made their decision based on the evidence that PMI could generate pre-market so this is before the product was on the market and they had to do this because of the law that exists in the U.S. They made the determination that it would be appropriate to give a reduced exposure plan to adult smokers in order to have greater choices because the data suggests that in the longer term there will be a substantial and measurable reduction in disease and premature death and that’s what they would like to be followed up and measured in the long term. So PMI is willing to make a decision based on pre-market evidence to give information to consumers but then require that there’s continued oversight in continuing longer term studies to make sure that what was observed in the pre-market setting is actually bono in the longer-term,” she added.
While being asked if PMI expects the FDA decision to influence other countries e.g South Korea where the government was a bit skeptical about the category, Dr Gilchrist said there’s really a consensus on the risk-profile of IQOS, it’s building from the U.S.’s FDA decision to Germany to the Netherlands to the UK. “We know that a lot of regulatory bodies elsewhere are kind of waiting to understand what the FDA decision is and what it means for them and countries like Israel for example were waiting to see what the FDA had to say. We really hope that this is the moment where regulators in each and every country take a part, look at the FDA decision, re-look at the evidence that prompted them to come to that decision. Look at what the UK is saying, the Netherlands and Germany and really focus back on the science and focus back on the best thing to do for other smokers who otherwise would continue to smoke. I really see it as a hopeful moment for the rest of the world and i do really hope that people take a part and look again at the evidence,” said Dr Gilchrist.
Asked why the FDA only issues this order for PMI’s products but not for other companies’ products, Dr Gilchrist said the FDA process in the U.S. is very product-specific, so you make an application for a given product and you cannot deviate from that. This is not a decision that applies to a category, is not a decision that applies to a company, is a decision that applies to a product. So PMI actually needed four applications, one for the device – the IQOS device itself and three different variants that were authorized at the same time and the authorization that PMI received on July 7.